Compounded semaglutide in 2026: what it is, how it differs from Wegovy, and is it still legal?

“Compounded semaglutide” was one of the most searched phrases in weight loss during 2023 and 2024, when telehealth sites sold it at flat monthly prices while the brand-name drugs were in short supply. Plenty of people still see it advertised, still have vials in the fridge, or hear about it in forums and wonder what they are actually looking at. This page explains what compounded semaglutide is, how it compares with Wegovy and Ozempic, what the FDA has seen go wrong with it, and, briefly, where it stands in 2026.

What is compounded semaglutide?

Compounded semaglutide is a version of the semaglutide molecule prepared by a pharmacy or outsourcing facility rather than made by the manufacturer of Wegovy and Ozempic. It is usually dispensed in multi-dose vials that the patient draws from with a syringe, and some sellers add other ingredients such as vitamin B12. Compounded drugs are not FDA-approved: the agency does not review them for safety, effectiveness or quality before they are marketed (FDA, concerns with unapproved GLP-1 drugs used for weight loss). The FDA has also said some compounders have used semaglutide salt forms, such as semaglutide sodium and semaglutide acetate, which are different active ingredients from the one in the approved drugs.

How does it compare with Wegovy and Ozempic?

The short version is that the brands have the trial evidence and the fixed doses, and the compounded product has neither. Wegovy’s weight-loss results come from randomized trials of the approved product: in STEP 1, semaglutide 2.4 mg weekly with a lifestyle program produced an average 14.9% weight loss over 68 weeks versus 2.4% on placebo (Wilding et al., NEJM 2021, PubMed), and in March 2026 the FDA approved a higher Wegovy HD 7.2 mg dose after the STEP UP trial reported about 20.7% mean weight loss. No trial has tested a compounded preparation.

For the same comparison across the whole GLP-1 class, including tirzepatide, see our guide to branded versus compounded GLP-1s.

What problems has the FDA seen with compounded semaglutide?

The most common problem is dosing. The FDA has received reports of adverse events, some requiring hospitalization, that may be linked to dosing errors with compounded injectable semaglutide, where patients measured and injected the wrong amount or clinicians miscalculated it (FDA). It has also received reports tied to compounded products prescribed above the labeled doses or stepped up faster than the label schedule, with nausea, vomiting, diarrhea, abdominal pain and constipation among the symptoms.

As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide. A report does not prove the drug caused the event, and because state-licensed pharmacies that are not outsourcing facilities are not required to report adverse events, the agency says the real number is likely higher. Other issues it lists: products shipped warm or without enough cold packs, and fraudulent “compounded” products labeled with pharmacies that do not exist. If you are using a multi-dose vial, the FDA advises throwing it away 28 days after first use, even if medicine remains, and using a new sterile needle and syringe for every dose.

Is compounded semaglutide still legal in 2026?

For most people, no: routine compounded semaglutide is no longer permitted, because the shortage that allowed it ended. The FDA determined the semaglutide shortage resolved on February 21, 2025, and the wind-down windows for pharmacies closed on April 22, 2025 (503A pharmacies) and May 22, 2025 (503B outsourcing facilities) (FDA compounder policy). A narrow route remains for an individual patient when a prescriber documents a clinical need the approved product cannot meet, and adding an ingredient like vitamin B12 does not by itself change that. The FDA has proposed leaving semaglutide off the 503B bulks list (FDA announcement); the comment period ran to July 30, 2026 (Federal Register), and as of October 12, 2026 it is still a proposal. In March 2026 the FDA sent warning letters to 30 telehealth companies over misleading compounded GLP-1 marketing (FDA). PeptideAgent’s semaglutide regulatory timeline keeps these dated actions in one place, each with its source.

How do you tell a legitimate GLP-1 program from a risky one?

A legitimate program starts with a real medical evaluation and leads with the approved products: Ozempic and Wegovy for semaglutide, Mounjaro and Zepbound for tirzepatide. The FDA’s own red-flag list for telehealth sellers is a good checklist: be wary of a company that claims its compounded drug is the same as an approved one, offers prices that seem too good to be true, does not require a screening and prescription from a licensed clinician, has no clinician available after the medicine arrives, or ships products that look different from before or carry labels with errors (FDA). For related questions, see how much a GLP-1 costs without insurance and semaglutide vs tirzepatide for weight loss.

Where does this leave you?

Compounded semaglutide is the same molecule in a very different package: no approval, no trials of its own, hand-measured doses, and a growing file of FDA adverse event and dosing-error reports. Since the shortage ended it is also no longer a routine option. If your goal is reaching a healthy weight, the next step is a genuine clinical evaluation, where a provider decides whether an approved GLP-1 fits you and at what dose.

See how getting a GLP-1 online works in 2026, or start with the questions worth bringing to that visit.

This page reflects FDA information available as of October 12, 2026 and is updated when the 503B proposal or the FDA’s guidance on compounded GLP-1s changes.